{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:12:05Z","timestamp":1648991525194},"reference-count":44,"publisher":"Medwave Estudios Limitada","issue":"Suppl3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medwave"],"DOI":"10.5867\/medwave.2016.6499","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T20:30:27Z","timestamp":1470429027000},"page":"e6499-e6499","source":"Crossref","is-referenced-by-count":0,"title":["\u00bfSon los nuevos antibi\u00f3ticos superiores a los betalact\u00e1micos para los pacientes hospitalizados, no cr\u00edticos, con neumon\u00eda adquirida en la comunidad?"],"prefix":"10.5867","volume":"16","author":[{"given":"Tom\u00e1s","family":"Reyes B","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Ortega G","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Sald\u00edas P","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3888","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"ref0","unstructured":"Cerrar"},{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijantimicag.2010.03.010","article-title":"Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.","volume":"36","author":"An","year":"2010","unstructured":"An MM, Zou Z, Shen H, Gao PH, Cao YB, Jiang YY. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010 Jul;36(1):58-65. | CrossRef | PubMed |","journal-title":"Int J Antimicrob Agents","ISSN":"http:\/\/id.crossref.org\/issn\/0924-8579","issn-type":"print"},{"issue":"7489","key":"ref2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/bmj.38334.591586.82","article-title":"Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.","volume":"330","author":"Mills","year":"2005","unstructured":"Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005 Feb 26;330(7489):456. | PubMed |","journal-title":"BMJ","ISSN":"http:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"issue":"9","key":"ref3","doi-asserted-by":"publisher","first-page":"CD004418","DOI":"10.1002\/14651858.cd004418.pub4","article-title":"Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.","author":"Eliakim-Raz","year":"2012","unstructured":"Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004418. | CrossRef | PubMed |","journal-title":"Cochrane Database Syst Rev","ISSN":"http:\/\/id.crossref.org\/issn\/1469-493X","issn-type":"print"},{"issue":"17","key":"ref4","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/archinte.165.17.1992","article-title":"Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials.","volume":"165","author":"Shefet","year":"2005","unstructured":"Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med. 2005 Sep 26;165(17):1992-2000. | PubMed |","journal-title":"Arch Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"issue":"12","key":"ref5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.","volume":"179","author":"Vardakas","year":"2008","unstructured":"Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ. 2008 Dec 2;179(12):1269-77. | CrossRef | PubMed |","journal-title":"CMAJ","ISSN":"http:\/\/id.crossref.org\/issn\/0820-3946","issn-type":"print"},{"issue":"5","key":"ref6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1179\/1973947812Y.0000000028","article-title":"Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.","volume":"24","author":"Yuan","year":"2012","unstructured":"Yuan X, Liang BB, Wang R, Liu YN, Sun CG, Cai Y, Yu XH, Bai N, Zhao TM, Cui JC, Chen LA. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials. J Chemother. 2012 Oct;24(5):257-67. | CrossRef | PubMed |","journal-title":"J Chemother","ISSN":"http:\/\/id.crossref.org\/issn\/1120-009X","issn-type":"print"},{"key":"ref7","unstructured":"Study report 1994 (DR-3355\/E05). Information reported in a systematic review. 1994. [No publicado] | Link |"},{"key":"ref8","unstructured":"Study report 1997 (106-92-20169). Information reported in a systematic review, 1997. [No publicado] | Link |"},{"key":"ref9","unstructured":"Study report 1999 (GFXB 3004). Information reported in a systematic review, 1999. [No publicado] | Link |"},{"key":"ref10","unstructured":"Study report 2000 (KF5501\/16). Information reported in a systematic review, 2000. [No publicado] | Link |"},{"issue":"6","key":"ref11","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1086\/516366","article-title":"Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.","volume":"26","author":"Aubier","year":"1998","unstructured":"Aubier M, Verster R, Regamey C, Geslin P, Vercken JB. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group. Clin Infect Dis. 1998 Jun;26(6):1312-20. | PubMed |","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia.","volume":"14","author":"Bohte","year":"1995","unstructured":"Bohte R, van't Wout JW, Lobatto S, Bluss\u00e9 van Oud Alblas A, Boekhout M, Nauta EH, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1995 Mar;14(3):182-7. | PubMed |","journal-title":"Eur J Clin Microbiol Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0934-9723","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Carbon C, Ariza H, Rabie WJ, Salvarezza CR, Elkharrat D, Rangaraj M, et al. Comparative study of levofloxacin and amoxycillin\/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. Clinical Microbiology and Infection. 1999 1999;12(5):724-32. | CrossRef |","DOI":"10.1111\/j.1469-0691.1999.tb00705.x"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1128\/AAC.36.4.833","article-title":"Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia.","volume":"36","author":"Carbon","year":"1992","unstructured":"Carbon C, L\u00e9ophonte P, Petitpretz P, Chauvin JP, Hazebroucq J. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1992 Apr;36(4):833-9. | PubMed |","journal-title":"Antimicrob Agents Chemother","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"52","key":"ref15","first-page":"1913","volume":"119","author":"Chuard","year":"1989","unstructured":"Chuard C, Regamey C. [Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin]. Schweiz Med Wochenschr. 1989 Dec 30;119(52):1913-6 | PubMed |","journal-title":"Schweiz Med Wochenschr","ISSN":"http:\/\/id.crossref.org\/issn\/0036-7672","issn-type":"print"},{"issue":"5","key":"ref16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0149-2918(97)80047-1","article-title":"Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.","volume":"19","author":"Donowitz","year":"1997","unstructured":"Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther. 1997 Sep-Oct;19(5):936-53. | PubMed |","journal-title":"Clin Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0149-2918","issn-type":"print"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0924-8579(00)00344-7","article-title":"An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem\/cilastatin in the intravenous treatment of hospitalised patients with pneumonia.","volume":"17","author":"Feldman","year":"2001","unstructured":"Feldman C, White H, O'Grady J, Flitcroft A, Briggs A, Richards G. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem\/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Int J Antimicrob Agents. 2001 Mar;17(3):177-88. | PubMed |","journal-title":"Int J Antimicrob Agents","ISSN":"http:\/\/id.crossref.org\/issn\/0924-8579","issn-type":"print"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.","volume":"41","author":"File","year":"1997","unstructured":"File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997 Sep;41(9):1965-72. | PubMed |","journal-title":"Antimicrob Agents Chemother","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1086\/378406","article-title":"Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin- Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adu.","volume":"38","author":"Fogarty","year":"2004","unstructured":"Fogarty C, Siami G, Kohler R, File TM, Tennenberg AM, Olson WH, et al. Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin- Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adu. Clin Infect Dis. 2004;38(Suppl 1):S16-S23. | Link |","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"},{"issue":"12","key":"ref20","first-page":"621","article-title":"Dimas Nu-ez JF, Saiz Garc\u00eda F.","volume":"19","author":"Geijo Mart\u00ednez","year":"2002","unstructured":"Geijo Mart\u00ednez MP, D\u00edaz de Tuesta Chow-Quan AM, Herranz CR, G\u00f3mez Criado C, Dimas Nu-ez JF, Saiz Garc\u00eda F. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization]. An Med Interna. 2002 Dec;19(12):621-5. | PubMed |","journal-title":"Med Interna","ISSN":"http:\/\/id.crossref.org\/issn\/1220-5818","issn-type":"print"},{"issue":"11","key":"ref21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/BF01700406","article-title":"Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.","volume":"16","author":"Genn\u00e9","year":"1997","unstructured":"Genn\u00e9 D, Siegrist HH, Humair L, Janin-Jaquat B, de Torrent\u00e9 A. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1997 Nov;16(11):783-8. | PubMed |","journal-title":"Eur J Clin Microbiol Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0934-9723","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. J Antimicrob Chemother. 1986 Nov;18 Suppl D:133-8. | PubMed |","DOI":"10.1093\/jac\/18.Supplement_D.133"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.","volume":"30","author":"Hagberg","year":"2002","unstructured":"Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection. 2002 Dec;30(6):378-86. | PubMed |","journal-title":"Infection","ISSN":"http:\/\/id.crossref.org\/issn\/0300-8126","issn-type":"print"},{"key":"ref24","unstructured":"Hong-yun L, Chao Q, Qian L, Qun F. Observation of the therapeutic effects of gatifloxacin on community acquired pneumonia. Chinese Journal of Antibiotics. 2007. | Link |"},{"issue":"9","key":"ref25","first-page":"387","volume":"39","author":"Jardim","year":"2003","unstructured":"Jardim JR, Rico G, de la Roza C, Obispo E, Urueta J, Wolff M, et al. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial]. Arch Bronconeumol. 2003 Sep;39(9):387-93. | PubMed |","journal-title":"Arch Bronconeumol","ISSN":"http:\/\/id.crossref.org\/issn\/0300-2896","issn-type":"print"},{"issue":"4","key":"ref26","first-page":"265","article-title":"Sequential intravenous\/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia.","volume":"5","author":"Johnson","year":"1996","unstructured":"Johnson RH, Levine S, Traub SL, Echols RM, Haverstock D, Arnold E, et al. Sequential intravenous\/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia. Infect Dis Clin Practice. 1996;5(4):265-72. | Link |","journal-title":"Infect Dis Clin Pract","ISSN":"http:\/\/id.crossref.org\/issn\/1056-9103","issn-type":"print"},{"issue":"15","key":"ref27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0025-7753(00)71625-3","volume":"115","author":"Kalbermatter","year":"2000","unstructured":"Kalbermatter V, Bagilet D, Diab M, Javkin E. [Oral levofloxacin versusintravenous ceftriaxone and amoxicillin\/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]. Med Clin (Barc).2000 Nov 4;115(15):561-3. | PubMed |","journal-title":"Med Clin (Barc )","ISSN":"http:\/\/id.crossref.org\/issn\/0025-7753","issn-type":"print"},{"issue":"4","key":"ref28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jemermed.2004.02.023","article-title":"Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.","volume":"27","author":"Katz","year":"2004","unstructured":"Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med. 2004 Nov;27(4):395-405. | PubMed |","journal-title":"J Emerg Med","ISSN":"http:\/\/id.crossref.org\/issn\/0736-4679","issn-type":"print"},{"issue":"10","key":"ref29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/BF01975846","article-title":"Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia.","volume":"10","author":"Kinasewitz","year":"1991","unstructured":"Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):872-7. | PubMed |","journal-title":"Eur J Clin Microbiol Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0934-9723","issn-type":"print"},{"issue":"6","key":"ref30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.11150\/kansenshogakuzasshi1970.58.525","volume":"58","author":"Kobayashi","year":"1984","unstructured":"Kobayashi H, Takamura K, Kono K, Onodera S, Sasaki N, Nagahama F, et al. [Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections]. Kansenshogaku Zasshi. 1984 Jun;58(6):525-55. | PubMed |","journal-title":"Kansenshogaku Zasshi","ISSN":"http:\/\/id.crossref.org\/issn\/0387-5911","issn-type":"print"},{"key":"ref31","unstructured":"Kohno S, Watanabe A, Aoki N, Niki Y, Kadota J, Fujita J, et al. Clinical phase III comparative study of intravenous levofloxacin and ceftriaxone in community-acquired pneumonia treatment. Jpn J Chemother. 59 (S-1): 32-45. | Link |"},{"issue":"8","key":"ref32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","article-title":"Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.","volume":"98","author":"L\u00e9ophonte","year":"2004","unstructured":"L\u00e9ophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004 Aug;98(8):708-20. | PubMed |","journal-title":"Respir Med","ISSN":"http:\/\/id.crossref.org\/issn\/0954-6111","issn-type":"print"},{"issue":"12","key":"ref33","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1183\/09031936.95.08121999","article-title":"Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.","volume":"8","author":"Lode","year":"1995","unstructured":"Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J. 1995 Dec;8(12):1999-2007. | PubMed |","journal-title":"Eur Respir J","ISSN":"http:\/\/id.crossref.org\/issn\/0903-1936","issn-type":"print"},{"issue":"6","key":"ref34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1469-0691.2004.00875.x","article-title":"Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.","volume":"10","author":"Lode","year":"2004","unstructured":"Lode H, Magyar P, Muir JF, Loos U, Kleutgens K; International Gatifloxacin Study Group. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. Clin Microbiol Infect. 2004 Jun;10(6):512-20. | PubMed |","journal-title":"Clin Microbiol Infect","ISSN":"http:\/\/id.crossref.org\/issn\/1198-743X","issn-type":"print"},{"issue":"2","key":"ref35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0163-4453(83)90464-4","article-title":"Erythromycin compared with a combination of ampicillin and amoxycillin as initial therapy for adults with pneumonia including Legionnaires' disease.","volume":"7","author":"Macfarlane","year":"1983","unstructured":"Macfarlane JT, Finch RG, Ward MJ, Rose DH. Erythromycin compared with a combination of ampicillin and amoxycillin as initial therapy for adults with pneumonia including Legionnaires' disease. J Infect. 1983 Sep;7(2):111-7. | PubMed |","journal-title":"J Infect","ISSN":"http:\/\/id.crossref.org\/issn\/0163-4453","issn-type":"print"},{"issue":"10","key":"ref36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.11150\/kansenshogakuzasshi1970.58.1083","volume":"58","author":"Miki","year":"1984","unstructured":"Miki F, Saito A, Tomizawa M, Nakayama I, Takebe K, Takashima T, et al. [Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method]. Kansenshogaku Zasshi. 1984 Oct;58(10):1083-113. | PubMed |","journal-title":"Kansenshogaku Zasshi","ISSN":"http:\/\/id.crossref.org\/issn\/0387-5911","issn-type":"print"},{"issue":"4","key":"ref37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/00365549850160710","article-title":"A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.","volume":"30","author":"Norrby","year":"1998","unstructured":"Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30(4):397-404. | PubMed |","journal-title":"Scand J Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0036-5548","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 1997 Dec;40 Suppl A:73-81. | PubMed |","DOI":"10.1093\/jac\/40.suppl_1.73"},{"issue":"1","key":"ref39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1378\/chest.119.1.185","article-title":"Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.","volume":"119","author":"Petitpretz","year":"2001","unstructured":"Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest. 2001 Jan;119(1):185-95. | PubMed |","journal-title":"Chest","ISSN":"http:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"issue":"6","key":"ref40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF01691581","article-title":"Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.","volume":"17","author":"Tr\u00e9moli\u00e8res","year":"1998","unstructured":"Tr\u00e9moli\u00e8res F, de Kock F, Pluck N, Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):447-53. | PubMed |","journal-title":"Eur J Clin Microbiol Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0934-9723","issn-type":"print"},{"issue":"8-9","key":"ref41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.patbio.2005.07.010","volume":"53","author":"Tr\u00e9moli\u00e8res","year":"2005","unstructured":"Tr\u00e9moli\u00e8res F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults]. Pathol Biol (Paris). 2005 Oct-Nov;53(8-9):503-10. Epub 2005 Sep 21. | PubMed |","journal-title":"Pathol Biol (Paris)","ISSN":"http:\/\/id.crossref.org\/issn\/0369-8114","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Vogel F, Lode H. The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia. J Antimicrob Chemother. 1991 Dec;28 Suppl C:81-6. | PubMed |","DOI":"10.1093\/jac\/28.suppl_C.81"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"Zeluff","year":"2007","unstructured":"Zeluff BJ, Lowe P, Koornhof HJ, Gentry LO. Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):69-71. | PubMed | Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother. 2010 Apr;65(4):608-18. | CrossRef | PubMed | Bantar C, Curcio D, Jasovich A, Bagnulo H, Arango A, Bavestrello L, et al. [Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II)]. Rev Chilena Infectol. 2010 Jun;27 Suppl 1:S9-S38. | CrossRef | PubMed | Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72. | PubMed |","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"}],"container-title":["Medwave"],"original-title":["Are new antibiotics better than beta-lactams for non-critical inpatients with community-acquired pneumonia?"],"link":[{"URL":"https:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T07:26:28Z","timestamp":1568273188000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":44,"journal-issue":{"issue":"Suppl3","published-online":{"date-parts":[[2016,8,5]]}},"URL":"https:\/\/doi.org\/10.5867\/medwave.2016.6499","relation":{},"ISSN":["0717-6384"],"issn-type":[{"value":"0717-6384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]}}}